These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 22991166)

  • 1. Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans.
    de Ru MH; van der Tol L; van Vlies N; Bigger BW; Hollak CE; Ijlst L; Kulik W; van Lenthe H; Saif MA; Wagemans T; van der Wal WM; Wanders RJ; Wijburg FA
    J Inherit Metab Dis; 2013 Mar; 36(2):247-55. PubMed ID: 22991166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy.
    Langereis EJ; van Vlies N; Church HJ; Geskus RB; Hollak CE; Jones SA; Kulik W; van Lenthe H; Mercer J; Schreider L; Tylee KL; Wagemans T; Wijburg FA; Bigger BW
    Mol Genet Metab; 2015 Feb; 114(2):129-37. PubMed ID: 25467058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I.
    Tomatsu S; Montaño AM; Oguma T; Dung VC; Oikawa H; de Carvalho TG; Gutiérrez ML; Yamaguchi S; Suzuki Y; Fukushi M; Sakura N; Barrera L; Kida K; Kubota M; Orii T
    J Inherit Metab Dis; 2010 Apr; 33(2):141-50. PubMed ID: 20162367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry.
    Tomatsu S; Montaño AM; Oguma T; Dung VC; Oikawa H; Gutiérrez ML; Yamaguchi S; Suzuki Y; Fukushi M; Barrera LA; Kida K; Kubota M; Orii T
    Mol Genet Metab; 2010 Feb; 99(2):124-31. PubMed ID: 19932038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis.
    Khan SA; Mason RW; Giugliani R; Orii K; Fukao T; Suzuki Y; Yamaguchi S; Kobayashi H; Orii T; Tomatsu S
    Mol Genet Metab; 2018 Sep; 125(1-2):44-52. PubMed ID: 29779903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy.
    Maccari F; Rigon L; Mantovani V; Galeotti F; Salvalaio M; D'Avanzo F; Zanetti A; Capitani F; Gabrielli O; Tomanin R; Volpi N
    J Mol Med (Berl); 2022 Aug; 100(8):1169-1179. PubMed ID: 35816218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of dermatan sulfate and heparan sulfate concentrations in serum, cerebrospinal fluid and urine in patients with mucopolysaccharidosis type I receiving intravenous and intrathecal enzyme replacement therapy.
    Zhang H; Dickson PI; Stiles AR; Chen AH; Le SQ; McCaw P; Beasley J; Millington DS; Young SP
    Clin Chim Acta; 2020 Sep; 508():179-184. PubMed ID: 32442432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III.
    de Ruijter J; de Ru MH; Wagemans T; Ijlst L; Lund AM; Orchard PJ; Schaefer GB; Wijburg FA; van Vlies N
    Mol Genet Metab; 2012 Dec; 107(4):705-10. PubMed ID: 23084433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI.
    Auray-Blais C; Bhérer P; Gagnon R; Young SP; Zhang HH; An Y; Clarke JT; Millington DS
    Mol Genet Metab; 2011 Jan; 102(1):49-56. PubMed ID: 20934363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses.
    Chuang CK; Lin HY; Wang TJ; Tsai CC; Liu HL; Lin SP
    Orphanet J Rare Dis; 2014 Sep; 9():135. PubMed ID: 25178307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationships between urinary glycosaminoglycan levels and phenotypes of mucopolysaccharidoses.
    Lin HY; Lee CL; Lo YT; Wang TJ; Huang SF; Chen TL; Wang YS; Niu DM; Chuang CK; Lin SP
    Mol Genet Genomic Med; 2018 Nov; 6(6):982-992. PubMed ID: 30296009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease.
    de Ruijter J; Ijlst L; Kulik W; van Lenthe H; Wagemans T; van Vlies N; Wijburg FA
    J Inherit Metab Dis; 2013 Mar; 36(2):271-9. PubMed ID: 22968582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incomplete biomarker response in mucopolysaccharidosis type I after successful hematopoietic cell transplantation.
    Kuiper GA; van Hasselt PM; Boelens JJ; Wijburg FA; Langereis EJ
    Mol Genet Metab; 2017 Sep; 122(1-2):86-91. PubMed ID: 28684085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 6 years of enzyme replacement therapy on plasma and urine glycosaminoglycans in attenuated MPS I patients.
    Coppa GV; Buzzega D; Zampini L; Maccari F; Galeazzi T; Pederzoli F; Gabrielli O; Volpi N
    Glycobiology; 2010 Oct; 20(10):1259-73. PubMed ID: 20538645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses.
    Zhang H; Wood T; Young SP; Millington DS
    Mol Genet Metab; 2015 Feb; 114(2):123-8. PubMed ID: 25458519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.
    Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S
    Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newborn screening and diagnosis of mucopolysaccharidoses.
    Tomatsu S; Fujii T; Fukushi M; Oguma T; Shimada T; Maeda M; Kida K; Shibata Y; Futatsumori H; Montaño AM; Mason RW; Yamaguchi S; Suzuki Y; Orii T
    Mol Genet Metab; 2013; 110(1-2):42-53. PubMed ID: 23860310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry.
    Kubaski F; Mason RW; Nakatomi A; Shintaku H; Xie L; van Vlies NN; Church H; Giugliani R; Kobayashi H; Yamaguchi S; Suzuki Y; Orii T; Fukao T; Montaño AM; Tomatsu S
    J Inherit Metab Dis; 2017 Jan; 40(1):151-158. PubMed ID: 27718145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normalization of glycosaminoglycan-derived disaccharides detected by tandem mass spectrometry assay for the diagnosis of mucopolysaccharidosis.
    Lin HY; Lo YT; Wang TJ; Huang SF; Tu RY; Chen TL; Lin SP; Chuang CK
    Sci Rep; 2019 Jul; 9(1):10755. PubMed ID: 31341247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary glycosaminoglycan (uGAG) excretion in healthy pediatric and adolescent population.
    Komosinska-Vassev K; Blat D; Olczyk P; Szeremeta A; Jura-Półtorak A; Winsz-Szczotka K; Klimek K; Olczyk K
    Clin Biochem; 2014 Sep; 47(13-14):1341-3. PubMed ID: 24956269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.